| Nome |
# |
|
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, file e27ce426-e257-2581-e053-d805fe0acbaa
|
2.701
|
|
High-dose Vitamin C enhances cancer immunotherapy, file e27ce42f-de1f-2581-e053-d805fe0acbaa
|
2.293
|
|
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma., file e27ce426-f515-2581-e053-d805fe0acbaa
|
1.549
|
|
EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer, file e27ce430-1013-2581-e053-d805fe0acbaa
|
1.087
|
|
Adaptive mutability of colorectal cancers in response to targeted therapies, file e27ce42e-f361-2581-e053-d805fe0acbaa
|
871
|
|
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, file e27ce42c-7e04-2581-e053-d805fe0acbaa
|
749
|
|
Blockade of EGFR and MEK Intercepts Heterogeneous Mechanisms of Acquired Resistance to Anti-EGFR Therapies in Colorectal Cancer, file e27ce426-f447-2581-e053-d805fe0acbaa
|
671
|
|
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution., file e27ce427-09bb-2581-e053-d805fe0acbaa
|
552
|
|
BRAF V600E is a determinant of sensitivity to proteasome inhibitors., file e27ce426-ffd1-2581-e053-d805fe0acbaa
|
481
|
|
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer, file e27ce42c-ac40-2581-e053-d805fe0acbaa
|
403
|
|
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer, file e27ce42e-fdba-2581-e053-d805fe0acbaa
|
361
|
|
BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer, file e27ce428-b1cc-2581-e053-d805fe0acbaa
|
332
|
|
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer, file e27ce42c-833b-2581-e053-d805fe0acbaa
|
326
|
|
Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model, file e27ce426-9df8-2581-e053-d805fe0acbaa
|
308
|
|
The chemosensitivity profile of retinoblastoma, file e27ce426-e403-2581-e053-d805fe0acbaa
|
307
|
|
Emergence of multiple EGFR extracellular mutations during cetuximab treatment in colorectal cancer, file e27ce427-2d1b-2581-e053-d805fe0acbaa
|
291
|
|
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs, file e27ce428-9f58-2581-e053-d805fe0acbaa
|
272
|
|
Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines, file e27ce428-fd78-2581-e053-d805fe0acbaa
|
252
|
|
The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets, file e27ce426-9d7d-2581-e053-d805fe0acbaa
|
243
|
|
Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor, file e27ce42c-b05b-2581-e053-d805fe0acbaa
|
241
|
|
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor, file e27ce42b-ad33-2581-e053-d805fe0acbaa
|
236
|
|
Design and synthesis of encorafenib-based BRAF-V600E degraders, file d8e03593-a5c7-4f96-9d2b-d9bc3af47ed2
|
232
|
|
Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer, file e27ce426-d50c-2581-e053-d805fe0acbaa
|
223
|
|
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer, file e27ce42a-9432-2581-e053-d805fe0acbaa
|
214
|
|
Retrospective multicenter study investigating the role of targeted next-generation sequencing of selected cancer genes in mucinous adenocarcinoma of the lung, file e27ce429-d149-2581-e053-d805fe0acbaa
|
208
|
|
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment, file e27ce42c-95cd-2581-e053-d805fe0acbaa
|
207
|
|
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations, file e27ce428-9706-2581-e053-d805fe0acbaa
|
204
|
|
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer, file e27ce42b-fd7d-2581-e053-d805fe0acbaa
|
204
|
|
VEGF blockade enhances the antitumor effect of BRAFV600E inhibition, file e27ce42b-2f9c-2581-e053-d805fe0acbaa
|
188
|
|
MGMT methylation assessed by methyl-BEAMing technique is a prognostic and predictive biomarker in glioblastoma and metastatic colorectal cancer patients, file e27ce427-0386-2581-e053-d805fe0acbaa
|
187
|
|
Exploiting DNA repair defects in colorectal cancer, file e27ce42d-e5d7-2581-e053-d805fe0acbaa
|
187
|
|
Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer, file e27ce428-ee7a-2581-e053-d805fe0acbaa
|
184
|
|
TGF-α and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells., file e27ce426-f1b3-2581-e053-d805fe0acbaa
|
172
|
|
The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination, file e27ce427-00cf-2581-e053-d805fe0acbaa
|
172
|
|
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients, file e27ce435-9a5d-2581-e053-d805fe0acbaa
|
171
|
|
A molecularly annotated platform of patient-derived xenografts (‘xenopatients’) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer, file e27ce426-de44-2581-e053-d805fe0acbaa
|
165
|
|
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells., file e27ce427-09b7-2581-e053-d805fe0acbaa
|
163
|
|
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers, file e27ce428-9c1b-2581-e053-d805fe0acbaa
|
162
|
|
Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma, file e27ce426-e406-2581-e053-d805fe0acbaa
|
158
|
|
Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer, file ec9c2092-a53b-4286-be12-aa515de4f3e9
|
152
|
|
A Genomic Analysis Workflow for Colorectal Cancer Precision Oncology, file e27ce42e-7735-2581-e053-d805fe0acbaa
|
149
|
|
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients, file e27ce428-f6ea-2581-e053-d805fe0acbaa
|
145
|
|
INHIBITION OF MEK AND PI3K/MTOR SUPPRESSES TUMOR GROWTH BUT DOES NOT CAUSE TUMOR REGRESSION IN PATIENT-DERIVED XENOGRAFTS OF RAS-MUTANT COLORECTAL CARCINOMAS, file e27ce426-d43e-2581-e053-d805fe0acbaa
|
144
|
|
Cancer cell adaptation to chemotherapy, file e27ce426-e412-2581-e053-d805fe0acbaa
|
143
|
|
Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer, file e27ce42c-4ba9-2581-e053-d805fe0acbaa
|
143
|
|
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours, file e27ce426-e400-2581-e053-d805fe0acbaa
|
135
|
|
Abstract 1163: Microenvironment targets in KRAS-mutated metastatic colorectal cancer, file e27ce42d-dfca-2581-e053-d805fe0acbaa
|
131
|
|
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia, file e27ce426-e4f1-2581-e053-d805fe0acbaa
|
130
|
|
Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients, file e27ce42b-34b5-2581-e053-d805fe0acbaa
|
123
|
|
Small nucleolar RNAs determine resistance to doxorubicin in human osteosarcoma, file e27ce430-5250-2581-e053-d805fe0acbaa
|
113
|
|
Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies, file e27ce42d-22a0-2581-e053-d805fe0acbaa
|
109
|
|
Evolving neoantigen profiles in colorectal cancers with DNA repair defects, file e27ce42e-a91a-2581-e053-d805fe0acbaa
|
105
|
|
High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib., file e27ce42e-9c36-2581-e053-d805fe0acbaa
|
102
|
|
Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus, file e27ce426-e419-2581-e053-d805fe0acbaa
|
98
|
|
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer, file e27ce429-176a-2581-e053-d805fe0acbaa
|
95
|
|
KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy., file e27ce426-df59-2581-e053-d805fe0acbaa
|
94
|
|
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies, file e27ce42d-8304-2581-e053-d805fe0acbaa
|
89
|
|
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling, file e27ce42c-6cb7-2581-e053-d805fe0acbaa
|
88
|
|
Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer, file e27ce42f-ed2c-2581-e053-d805fe0acbaa
|
88
|
|
MET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF mutated colorectal cancer, file e27ce429-c87b-2581-e053-d805fe0acbaa
|
85
|
|
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer, file e27ce427-3a7d-2581-e053-d805fe0acbaa
|
83
|
|
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients, file e27ce42a-e247-2581-e053-d805fe0acbaa
|
82
|
|
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility, file e27ce429-02da-2581-e053-d805fe0acbaa
|
81
|
|
Tumor heterogeneity and Lesion-Specific response to targeted therapy in colorectal cancer, file e27ce429-1433-2581-e053-d805fe0acbaa
|
80
|
|
Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer, file e27ce42c-4bab-2581-e053-d805fe0acbaa
|
78
|
|
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin, file e27ce435-7e08-2581-e053-d805fe0acbaa
|
75
|
|
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer, file e27ce430-7fc7-2581-e053-d805fe0acbaa
|
73
|
|
Circulating methylated DNA to monitor the dynamics of RAS mutation clearance in plasma from metastatic colorectal cancer patients, file e27ce431-364d-2581-e053-d805fe0acbaa
|
69
|
|
Werner helicase is a synthetic-lethal vulnerability in Mismatch Repair-Deficient Colorectal Cancer Refractory to Targeted Therapies, Chemotherapy and Immunotherapy, file e27ce432-19bb-2581-e053-d805fe0acbaa
|
66
|
|
BRAF V600E is a determinant of sensitivity to proteasome inhibitors., file e27ce426-ffd2-2581-e053-d805fe0acbaa
|
63
|
|
Homeobox B9 mediates resistance to anti-VEGF therapy in colorectal cancer patients, file e27ce42b-6c73-2581-e053-d805fe0acbaa
|
63
|
|
Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation, file e27ce42d-dfce-2581-e053-d805fe0acbaa
|
62
|
|
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor, file e27ce42b-c004-2581-e053-d805fe0acbaa
|
61
|
|
Kras mutations and resistance to anti-egfr treatment, file e27ce426-9d7f-2581-e053-d805fe0acbaa
|
55
|
|
Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3., file e27ce426-f670-2581-e053-d805fe0acbaa
|
54
|
|
Evaluation of the preclinical efficacy of lurbinectedin in malignant pleural mesothelioma, file e27ce432-054f-2581-e053-d805fe0acbaa
|
51
|
|
RET fusions in a small subset of advanced colorectal cancers at risk of being neglected, file e27ce42c-534d-2581-e053-d805fe0acbaa
|
50
|
|
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer, file e27ce42a-bea3-2581-e053-d805fe0acbaa
|
48
|
|
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients, file e27ce435-9a5b-2581-e053-d805fe0acbaa
|
45
|
|
Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer, file e27ce42b-0741-2581-e053-d805fe0acbaa
|
42
|
|
Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers, file e27ce42e-9715-2581-e053-d805fe0acbaa
|
38
|
|
RAS Mutation Conversion in Bevacizumab-Treated Metastatic Colorectal Cancer Patients: A Liquid Biopsy Based Study, file e27ce435-30b3-2581-e053-d805fe0acbaa
|
37
|
|
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin, file e27ce42f-3951-2581-e053-d805fe0acbaa
|
30
|
|
Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance, file e61b9084-f49d-4af2-9203-f2bd324869f9
|
30
|
|
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer., file e27ce426-e096-2581-e053-d805fe0acbaa
|
22
|
|
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells, file eddce5b7-5d9a-414e-811a-e6a359372a96
|
22
|
|
A modified fluctuation-test framework characterizes the population dynamics and mutation rate of colorectal cancer persister cells, file 0680489c-fa68-4090-80fb-bcf874f958a2
|
21
|
|
Acquired resistance to EGFR-targeted therapies in colorectal cancer., file e27ce426-f1b5-2581-e053-d805fe0acbaa
|
20
|
|
Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer, file e27ce42d-8306-2581-e053-d805fe0acbaa
|
20
|
|
Mouse models of Kras mutant colorectal cancer: valuable GEMMs for drug testing?, file e27ce42a-c1d8-2581-e053-d805fe0acbaa
|
19
|
|
Dual VEGFA/BRAF targeting boosts PD-1 blockade in melanoma through GM-CSF-mediated infiltration of M1 macrophages, file 0f7b36ae-8da4-4965-9703-76f0c210267c
|
15
|
|
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling, file e27ce42c-534b-2581-e053-d805fe0acbaa
|
15
|
|
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer, file e27ce428-f1c8-2581-e053-d805fe0acbaa
|
14
|
|
Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAFV600E Protein, file d8cded6f-e57e-4e8c-87da-877e19c5510e
|
11
|
|
Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase, file e27ce42d-dabd-2581-e053-d805fe0acbaa
|
9
|
|
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients, file f2908de7-b6e6-471c-be4a-be1fde87a37a
|
9
|
|
Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment, file e27ce42c-8aea-2581-e053-d805fe0acbaa
|
8
|
|
Adaptive mutability of colorectal cancers in response to targeted therapies, file e27ce42e-f362-2581-e053-d805fe0acbaa
|
8
|
|
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients, file e27ce435-9a5c-2581-e053-d805fe0acbaa
|
8
|
|
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, file e27ce42c-77f6-2581-e053-d805fe0acbaa
|
7
|
| Totale |
22.032 |